J.P. Morgan analyst Anupam Rama maintained a Buy rating on AlloVir (ALVR – Research Report) on May 10 and set a price target of $32.00. The company’s shares closed last Wednesday at $3.26, close to its 52-week low of $3.21.
According to TipRanks.com, Rama is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.3% and a 36.7% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Protagonist Therapeutics, and Springworks Therapeutics.
Currently, the analyst consensus on AlloVir is a Strong Buy with an average price target of $39.00, implying a 920.9% upside from current levels. In a report issued on May 5, SVB Securities also reiterated a Buy rating on the stock with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on AlloVir’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $57.94 million. In comparison, last year the company had a GAAP net loss of $30.92 million.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALVR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm’s pipeline includes ALVR106, ALVR109, ALVR108, and others. The company’s product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Read More on ALVR:
- Stock Futures Down on Discouraging April Inflation Data
- J.P. Morgan Maintains a Buy Rating on SOPHiA GENETICS (SOPH)
- GoHealth (GOCO) Receives a Hold from RBC Capital
- Cantor Fitzgerald Thinks Village Farms International’s Stock is Going to Recover
- Analysts Are Bullish on Top Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Aeglea Biotherapeutics (AGLE)
